検索
GSK plc
GSKウォッチリストに追加
50.470USD
+0.060+0.12%
取引時間 （ET）15分遅れの株価
102.32B時価総額
13.01直近12ヶ月PER
詳細情報 GSK plc 企業名
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
GSK plcの企業情報
企業コードGSK
会社名GSK plc
上場日May 22, 1972
最高経営責任者「CEO」Waterhouse (Deborah)
従業員数68629
証券種類Depository Receipt
決算期末May 22
本社所在地980 Great West Road
都市BRENTFORD
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United Kingdom
郵便番号TW8 9GS
電話番号442080475000
ウェブサイトhttps://www.gsk.com/
企業コードGSK
上場日May 22, 1972
最高経営責任者「CEO」Waterhouse (Deborah)
GSK plcの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.15K
+0.00%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
41.23K
+0.76%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.45K
+0.75%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.00K
+0.70%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--
Ms. Victoria Anne Whyte
Ms. Victoria Anne Whyte
Company Secretary
Company Secretary
--
--
Mr. Phil C. Thomson
Mr. Phil C. Thomson
President - Global Affairs
President - Global Affairs
--
--
Dame Emma N. Walmsley
Dame Emma N. Walmsley
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Luke Miels
Mr. Luke Miels
Chief Executive Officer - Designate, Director
Chief Executive Officer - Designate, Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.15K
+0.00%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
41.23K
+0.76%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.45K
+0.75%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.00K
+0.70%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--
収益内訳
通貨: USD更新時刻: Mon, Apr 6
通貨: USD更新時刻: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
HIV
10.12B
23.53%
Respiratory
9.31B
21.64%
Immuno-inflammation
5.02B
11.66%
Shingles
4.69B
10.89%
Established Vaccines
4.11B
9.55%
他の
9.78B
22.73%
地域別USD
会社名
収益
比率
US
22.20B
51.61%
Rest of world
10.90B
25.33%
Europe
9.92B
23.06%
事業別
地域別
事業別USD
会社名
収益
比率
HIV
10.12B
23.53%
Respiratory
9.31B
21.64%
Immuno-inflammation
5.02B
11.66%
Shingles
4.69B
10.89%
Established Vaccines
4.11B
9.55%
他の
9.78B
22.73%
株主
更新時刻: Thu, May 7
更新時刻: Thu, May 7
株主統計
種類
株主統計
株主統計
比率
Dodge & Cox
3.38%
Fidelity Management & Research Company LLC
2.81%
Fisher Investments
1.70%
PRIMECAP Management Company
1.24%
JTC Employer Solutions Trusteee Ltd
0.71%
他の
90.16%
株主統計
株主統計
比率
Dodge & Cox
3.38%
Fidelity Management & Research Company LLC
2.81%
Fisher Investments
1.70%
PRIMECAP Management Company
1.24%
JTC Employer Solutions Trusteee Ltd
0.71%
他の
90.16%
種類
株主統計
比率
Investment Advisor
9.05%
Investment Advisor/Hedge Fund
8.17%
Research Firm
1.01%
Hedge Fund
0.92%
Pension Fund
0.13%
Bank and Trust
0.10%
Individual Investor
0.06%
Family Office
0.03%
Family Office
0.02%
他の
80.52%
機関投資家保有株
更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
1585
393.46M
19.40%
-23.49M
2025Q4
1508
391.56M
19.21%
-21.81M
2025Q3
1474
388.63M
19.14%
-11.70M
2025Q2
1478
378.08M
18.54%
+5.70M
2025Q1
1494
378.46M
18.50%
+5.08M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Dodge & Cox
68.52M
3.37%
-9.89M
-12.61%
Dec 31, 2025
Fidelity Management & Research Company LLC
56.97M
2.81%
+1.14M
+2.04%
Dec 31, 2025
Fisher Investments
33.20M
1.64%
+968.37K
+3.00%
Dec 31, 2025
PRIMECAP Management Company
25.13M
1.24%
-636.79K
-2.47%
Dec 31, 2025
JTC Employer Solutions Trusteee Ltd
14.43M
0.71%
-169.18K
-1.16%
Dec 31, 2025
Wellington Management Company, LLP
12.56M
0.62%
+9.14M
+267.14%
Dec 31, 2025
Acadian Asset Management LLC
8.96M
0.44%
+6.18M
+221.47%
Dec 31, 2025
Fidelity Institutional Asset Management
8.15M
0.4%
+179.23K
+2.25%
Dec 31, 2025
Holocene Advisors, LP
8.12M
0.4%
+1.02M
+14.31%
Dec 31, 2025
T. Rowe Price International Ltd
7.89M
0.39%
-56.47K
-0.71%
Dec 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
VanEck Pharmaceutical ETF
10.83%
The Opal International Dividend Income ETF
4.41%
Sound Equity Dividend Income ETF
3.97%
Keating Active ETF
3.88%
USCF Dividend Income Fund
3.83%
Brandes International ETF
2.87%
Altrius Global Dividend ETF
2.58%
Fidelity Blue Chip Value ETF
1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
1.17%
Avantis International Large Cap Value ETF
1.02%
詳細を見る
VanEck Pharmaceutical ETF
比率10.83%
The Opal International Dividend Income ETF
比率4.41%
Sound Equity Dividend Income ETF
比率3.97%
Keating Active ETF
比率3.88%
USCF Dividend Income Fund
比率3.83%
Brandes International ETF
比率2.87%
Altrius Global Dividend ETF
比率2.58%
Fidelity Blue Chip Value ETF
比率1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
比率1.17%
Avantis International Large Cap Value ETF
比率1.02%
配当金
過去5年間の配当金総支払額は
15.69B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
May 04, 2026
GSK.NB Approximate interim Cash Dividend of gross USD 0.461074 paid on Jul 09, 2026 going ex on May 15, 2026
May 15, 2026
Jul 09, 2026
May 15, 2026
Apr 29, 2026
GSK.NB Interim Cash Dividend of gross paid on Jul 09, 2026 going ex on May 15, 2026
May 15, 2026
Jul 09, 2026
May 15, 2026
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.434774 paid on Jul 10, 2025 going ex on May 16, 2025
May 16, 2025
Jul 10, 2025
May 16, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.42996 paid on Oct 09, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Oct 09, 2025
Aug 15, 2025
Feb 05, 2025
GSK.NB Approximate final Cash Dividend of gross USD 0.417088 paid on Jan 08, 2026 going ex on Nov 14, 2025
Nov 14, 2025
Jan 08, 2026
Nov 14, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.407568 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Feb 05, 2025
GSK.NB Approximate interim Cash Dividend of gross paid on Apr 09, 2026 going ex on Feb 20, 2026
Feb 20, 2026
Apr 09, 2026
Feb 20, 2026
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
詳細を見る
株式分割
日付
配当落ち日
種類
比率
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
日付
配当落ち日
種類
比率
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
